Pfizer
Gulmira Propper is currently serving as the Manager of the Pharmaceutical Marketing Rotational Program at Pfizer, where responsibilities include three rotations focused on US DMD Gene Therapy, US ABRYSVO - Maternal, and Global Lorbrena, starting in September 2023. Previously, Gulmira was a Pharmaceutical Marketing Summer Associate at Pfizer, working on the US Eliquis project in summer 2022. Prior experience includes roles in Strategy and M&A at PerkinElmer, Inc. from September 2018 to August 2021, progressing from Associate to Manager. Additionally, Gulmira authored the book "Silk Road Recipes: Parida's Uyghur Cookbook," with proceeds supporting the Uyghur Human Rights Project, in September 2020. Gulmira began a career as an Analyst at CMA Strategy Consulting from August 2017 to August 2018. Academically, Gulmira holds an MBA in Health Care Management from The Wharton School (2021-2023) and a dual B.A. in Economics and Health and Human Biology from Brown University (2013-2017).
This person is not in the org chart
This person is not in any teams
Pfizer
614 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.